

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number
WO 01/92206 A1

- (51) International Patent Classification⁷: C07C 231/00, 233/05 (74) Agents: LESSLER, Jay, P. et al.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022-7513 (US).
- (21) International Application Number: PCT/US01/18118 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 4 June 2001 (04.06.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/209,039 2 June 2000 (02.06.2000) US (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): EMI-SPHERE TECHNOLOGIES, INC. [US/US]; 765 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

- (72) Inventors; and
(75) Inventors/Applicants (*for US only*): BAY, William, E. [US/US]; 20 Woodland Way, Ridgefield, CT 06877 (US). CORVINO, JoAnne, P. [US/US]; 59 White Street, Harrison, NY 10528 (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/92206 A1

(54) Title: METHOD OF PREPARING SALICYLAMIDES

(57) Abstract: The present invention provides a fast, high yield method for preparing salicylamide intermediates. The method comprises reacting a C₄ or higher alkyl ester of salicylic acid or derivative thereof with at least one amine selected from the group consisting of monoalkylamines, dialkylamines, ammonia, and any combination of any of the foregoing in alcohol to yield the salicylamide. The C₄ or higher alkyl ester of salicylic acid or a derivative thereof is preferably prepared by reacting salicylic acid or a derivative thereof with a C₄ or higher alcohol in presence of at least one of sulfuric acid, a sulfonic acid, and a mineral acid. This process for preparing salicylamide intermediates from salicylic acid or derivative thereof generally has a cycle time of about 2 days, and yields about 95 % of a 99 % pure material. In comparison, when a C₃ or lower alkyl ester is used in lieu of the C₄ or higher alkyl ester, the process generally has a cycle time of 7-9 days and yields about 60 % of a 95 % pure material. Methods of preparing an alkylated salicylamide are also provided.

5

METHOD OF PREPARING SALICYLAMIDES

This application claims the benefit of U.S. Provisional Application No. 60/209,039, filed on June 2, 2000, which is hereby incorporated by reference.

10

FIELD OF THE INVENTION

The present invention relates to methods of preparing salicylamide intermediates, C₄ or higher alkyl esters of salicylic acid and derivatives thereof, and alkylated salicylamides.

15

BACKGROUND OF THE INVENTION

U.S. Patent Nos. 5,773,647 and 5,866,536 disclose compositions for the oral delivery of active agents, such as heparin and calcitonin, with modified amino acids, such as *N*-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), sodium *N*-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), and sodium *N*-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC).

20

There is a need for a fast and efficient method for preparing salicylamides and alkylated salicylamides from salicylic acid and derivatives thereof.

SUMMARY OF THE INVENTION

25

The present invention provides a fast, high yield method for preparing salicylamide intermediates. The method comprises reacting a C₄ or higher alkyl ester of salicylic acid or a derivative thereof with at least one amine selected from the group consisting of monoalkylamines, dialkylamines, ammonia, and any combination of any of the foregoing in alcohol to yield the salicylamide.

30

The C₄ or higher alkyl ester of salicylic acid or a derivative thereof is preferably prepared by reacting salicylic acid or a derivative thereof with a C₄ or higher

-2-

alcohol in the presence of at least one of sulfuric acid, a sulfonic acid, and a mineral acid. (i.e., an inorganic acid). This process for preparing salicylamide intermediates from salicylic acid or a derivative thereof generally has a cycle time of about 2 days, and yields about 95% of a 99% pure material. In comparison, when a C₃ or lower alkyl ester is used
5 in lieu of the C₄ or higher alkyl ester, the process generally has a cycle time of 7-9 days and yields about 60% of a 95% pure material.

Yet another embodiment is a method of preparing an alkylated salicylamide comprising (a) reacting a C₄ or higher alkyl ester of salicylic acid or a derivative thereof with at least one amine selected from the group consisting of
10 monoalkylamines, dialkylamines, ammonia, and any combination of any of the foregoing in alcohol to yield a first salicylamide; and (b) alkylating the first salicylamide to form the alkylated salicylamide.

Yet another embodiment is a method of preparing an alkylated salicylamide comprising (a) reacting salicylic acid or a derivative thereof with a C₄ or
15 higher alcohol in the presence of at least one of sulfuric acid, a sulfonic acid, and a mineral acid to form a C₄ or higher alkyl ester of salicylic acid or a derivative thereof; (b) converting the C₄ or higher alkyl ester into a first salicylamide; and (c) alkylating the first salicylamide to form the alkylated salicylamide.

20 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a fast, high yield method for preparing salicylamide intermediates. As a result, the cycle time for preparing alkylated salicylamides, such as 5-CNAC, via this intermediate is drastically reduced.


The terms "alkyl", "alkenyl", and "alkynyl" as used herein include linear
25 and branched alkyl, alkenyl, and alkynyl substituents, respectively.

-3-

Preparation of C₄ or Higher Alkyl Esters of Salicylic Acid and Derivatives Thereof

The C₄ or higher alkyl ester may be prepared by reacting salicylic acid or a derivative thereof with a C₄ or higher alcohol in the presence of at least one of sulfuric acid, a sulfonic acid, and a mineral acid.

5 According to one embodiment, the salicylic acid or derivative thereof has the formula



where

15 R¹, R², R³, and R⁴ are independently hydrogen, -OH, -O-R⁵, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, carboxy, substituted or unsubstituted alkoxycarbonyl, halogen, nitrile, -OC(O)CH₃, -SO₃H, or -NR⁶R⁷;

R⁵ is hydrogen, alkyl, or aryl; and

R⁶ and R⁷ are independently hydrogen, C₁-C₄ alkyl, or oxygen.

20 The alkyl, alkenyl, alkoxy and aryl groups of R¹, R², R³, R⁴, and R⁵ may be substituted with, for example, -OH, F, and alkyl and aryl groups. R¹, R², R³, R⁴, and R⁵ may be C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, or C₁-C₁₈ alkoxy. In particular, R¹, R², R³, R⁴, and R⁵ may be C₁-C₄ alkyl, C₂-C₄ alkenyl, or C₁-C₄ alkoxy. The alkoxycarbonyl group of R¹, R², R³, R⁴, and R⁵ may be substituted with, for example, alkyl groups.

25 Preferred halogens for R¹, R², R³, and R⁴ are chlorine, bromine, and fluorine. Preferred alkyl groups for R¹, R², R³, and R⁴ include, but are not limited to, methyl and ethyl. Preferred alkoxy groups for R¹, R², R³, and R⁴ include, but are not limited to, methoxy and ethoxy.

30 According to one preferred embodiment, R¹, R², R³, and R⁴ are independently hydrogen, methoxy, or chlorine. According to a more preferred

-4-

embodiment, R^1 , R^2 , R^3 , and R^4 are hydrogen. According to another more preferred embodiment, R^1 , R^3 , and R^4 are hydrogen and R^2 is chlorine. According to yet another embodiment, R^1 , R^2 , and R^4 are hydrogen and R^3 is methoxy.

Suitable alcohols include those that form two-phase azeotropes. Examples
5 of such alcohols include, but are not limited to, linear and branched primary alcohols. Preferred alcohols include, but are not limited to, linear and branched C_4 - C_8 alcohols (*i.e.* butanol, pentanol, hexanol, heptanol, and octanol). A more preferred alcohol is *n*-butanol. Since propanol and lower alcohols do not form two-phase azeotropes, reactions with these alcohols produce solutions in which the ester product is difficult to separate
10 from the water by-product.

A non-limiting example of a suitable sulfonic acid is *p*-toluene sulfonic acid. Suitable mineral acids include, but are not limited to, hydrochloric acid, hydrogen bromide, phosphoric acid, and any combination of any of the foregoing.


Generally, the reaction mixture includes a molar excess of C_4 or higher
15 alcohol relative to salicylic acid or derivative thereof. The reaction mixture broadly includes from about 2% by weight to the saturation concentration of salicylic acid or derivative thereof, based on 100% weight of reaction mixture. Generally, from about 1 to 30% by weight of at least one of sulfuric acid, a sulfonic acid, and a mineral acid is included in the reaction mixture, based on 100% weight of reaction mixture. According
20 to one embodiment, the reaction mixture includes from about 5 to about 15% by weight of at least one of sulfuric acid, a sulfonic acid, and a mineral acid, based on 100% weight of reaction mixture.

This reaction is typically performed at a temperature of from about 90 to about 120° C and preferably at from about 95 to about 117° C. Generally, this reaction
25 is performed at a pressure of from about 0.8 to about 2.0 atm and preferably at from about 0.95 to about 1.05 atm. According to a preferred embodiment, this reaction is performed under a dry nitrogen (N_2) blanket.

Water is preferably removed during or after formation of the C_4 or higher alkyl ester. More preferably, water is removed during the reaction, such as by azeotropic
30 removal.

-5-

This method can produce C₄ or higher alkyl esters of salicylic acid and derivatives having the formula:



where

10 R¹, R², R³, and R⁴ are defined as above; and

R¹² is a linear or branched C₄ or higher alkyl.

Preferably, R¹² is a linear or branched C₄-C₈ alkyl and more preferably R¹² is n-butyl.

15

Preparation of Salicylamide from

C₄ or Higher Alkyl Esters of Salicylic Acid and Derivatives Thereof

The C₄ or higher alkyl ester of salicylic acid or derivative thereof is reacted with at least one amine selected from the group consisting of monoalkylamines, dialkylamines, ammonia, and any combination of any of the foregoing in alcohol to yield the (unprotected and unactivated) salicylamide. The C₄ or higher alkyl ester is preferably a C₄-C₈ alkyl ester and more preferably a butyl ester, such as an n-butyl ester.

20

Suitable alcohols include, but are not limited to, C₁-C₄ alcohols, such as methanol, ethanol, and propanol; glycols, such as ethylene glycol; and any combination of any of the foregoing. A preferred alcohol is methanol. Since methanol has the greatest solubility for ammonia of all the alcohols, it promotes the reaction more than any other alcohol when ammonia is used.

25

Suitable monoalkylamines include, but are not limited to, monomethylamine, monoethylamine, and any combination of any of the foregoing. Suitable dialkylamines include, but are not limited to, dimethylamine, diethylamine, and

-6-


any combination of any of the foregoing. According to one preferred embodiment, the amine is ammonia and more preferably anhydrous ammonia.

Generally, the reaction mixture contains a molar excess of amine relative to the alkyl ester. The molar ratio of amine to alkyl ester preferably ranges from about 5:1 to about 50:1 and more preferably from about 5:1 to about 15:1.

When water is present, the reaction slows down and the ester can be hydrolyzed back to the starting salicylic acid or derivative thereof. Accordingly, the reaction is preferably performed in an environment substantially free of water and more preferably in an environment having less than about 1% by weight of water (based on 100% weight of reaction mixture). For example, the reaction may be performed under a dry nitrogen (N₂) or ammonia (NH₃) blanket. Preferably, the ammonia and methanol are applied under anhydrous conditions.

The reaction is typically performed at a temperature of from about 25 to about 80° C and preferably at from about 35 to about 50° C. Generally, the reaction is performed at a pressure of from about 1 to about 10 atm and preferably at from about 2 to about 3 atm.

Salicylamide intermediates which may be prepared by this method include, but are not limited to, those having the formula



where R¹, R², R³, and R⁴ are defined as above. Special mention is made of 5-chlorosalicylamide and 4-methoxy salicylamide.

The salicylamide intermediate may be purified by any method known in the art. For example, it may be purified by recrystallization or by fractionation on one or more solid chromatographic supports, alone or linked in tandem. Suitable

-7-

recrystallization solvent systems include, but are not limited to, acetonitrile, methanol, and tetrahydrofuran. Fractionation may be performed on a suitable chromatographic support such as alumina, using methanol/n-propanol mixtures as the mobile phase; reverse phase chromatography using trifluoroacetic acid/acetonitrile mixtures as the mobile phase; and ion exchange chromatography using water or an appropriate buffer as the mobile phase. When anion exchange chromatography is performed, preferably a 0-500 mM sodium chloride gradient is employed.


Preparation of Alkylated Salicylamides

Alkylated salicylamides, such as 5-CNAC, may be prepared from the salicylamide intermediates of the present invention, such as by the methods described in International Publication No. WO 00/46182 and International Patent Application No. PCT/US01/09154, both of which are hereby incorporated by reference. Generally, the unprotected and unactivated (unprotected/unactivated) salicylamide intermediate is alkylated to form the alkylated salicylamide. One preferred method of alkylating the salicylamide intermediate is by (i) protecting and activating the unprotected/unactivated salicylamide to form a protected and activated (protected/activated) salicylamide; (ii) alkylating the protected/activated salicylamide with an alkylating agent to form a protected/activated alkylated salicylamide; and (iii) deprotecting and deactivating the protected/activated alkylated salicylamide to form the alkylated salicylamide.

The term "protected salicylamide" is defined herein as a salicylamide where the hydroxy moiety of the salicyl group has been protected to prevent reaction of the hydroxy moiety. The term "activated salicylamide" is defined herein as a salicylamide where the nitrogen atom of the amide group has been activated so that the nitrogen atom is in a more reactive condition, *i.e.*, more prone to reaction.

Suitable protected/activated salicylamides include, but are not limited to, compounds having the formula

-8-




where

R^1 , R^2 , R^3 , and R^4 are defined as above;

R^8 is a protecting group;

R^9 is an activating group; or

R^8 and R^9 are combined to form a cyclic group, *i.e.*, R^8 and R^9 form a single group that forms a heterocycle with the oxygen atom and nitrogen atom of the amide moiety. For example, carsalam, which has the formula




is a suitable protected/activated salicylamide.

The protecting and activating groups may be the same or different. The protecting and activating groups may be separate moieties (each attached to one of the hydroxy or amide moieties) or a single moiety (attached to both the hydroxy and amide moieties).

Suitable protecting groups include, but are not limited to, $-C(O)CH_3$; $-C(O)F_3$; $-S(O)_2CH_3$; $-S(O)_2CF_3$; benzyl; silyl; tetrahydropyranyl; and methylenealkoxy, such as methylenemethoxy and methyleneethoxy. Suitable activating groups include, but are not limited to, $-C(O)CH_3$; $-C(O)CF_3$; $-S(O)_2CH_3$; and $-S(O)_2CF_3$. Preferably, R^8 and R^9 are combined to form a cyclic group which protects the hydroxy moiety and activates the nitrogen atom of the amide moiety. More preferably, combined R^8 and R^9 are $-C(O)-$ or $-S(O)_2-$.

-9-

Preferred protected/activated salicylamides include, but are not limited to, carsalam and derivatives thereof having the formula



where R¹, R², R³, and R⁴ are defined as above.

One method of preparing the protected/activated salicylamide of the present invention comprises protecting the hydroxy moiety of the salicylamide intermediate and activating the amide moiety of the salicylamide intermediate. The protecting and activating steps may be performed in any order, but are preferably performed simultaneously. For example, the protecting step may be performed before performing the activating step.

The hydroxy moiety of the salicylamide intermediate may be protected by methods known in the art. For example, the hydroxy moiety may be protected by reacting the salicylamide with a protecting agent, such as an activated halide. The resulting salicylamide has a protecting group attached to the oxygen atom of the hydroxy moiety. Examples of activated halides include, but are not limited to, acyl halides; silyl halides, such as silyl chlorides; benzyl halides; and methylene alkoxy halides, such as methylene methoxy halides and methylene ethoxy halides. Preferably, the reaction with an activated halide is performed in the presence of a base, such as potassium carbonate, triethylamine, or pyridine.

Another example of a protecting agent is an activated ether. Examples of activated ethers include, but are not limited to, dihydropyranyl ether. Preferably, the activated ether is reacted with the salicylamide under acid catalysis conditions, such as with sulfuric acid, para-toluene sulfonic acid, or camphor sulfonic acid in methylene chloride, tetrahydrofuran, or toluene.

-10-

The amide moiety of the salicylamide intermediate may be activated by methods known in the art. For example, the amide moiety may be activated by reacting the salicylamide with an activating agent, such as an acyl halide, acyl anhydride, sulfonyl halide, or sulfonyl anhydride. The resulting salicylamide has an activating group attached to the nitrogen atom of the amide moiety. Suitable acyl halides include, but are not limited to, those described above for protecting the hydroxy moiety of the salicylamide. Preferably, the activating agent is reacted with the salicylamide in the presence of a base, such as potassium carbonate, triethylamine, or pyridine.

In the preparation of carsalam and the aforementioned derivatives thereof, the protecting and activating steps are typically performed simultaneously and the protecting and activating groups are a single group attached to both the hydroxy and amide moieties. One method of preparing carsalam and the derivatives thereof is by reacting the corresponding (unprotected and unactivated) salicylamide with an alkyl chloroformate, such as ethyl chloroformate; a phenyl chloroformate; or an imidazole alkoxy carbonyl.

The protected/activated salicylamide may be alkylated by the methods known in the art for alkylating phthalimide to form a primary amine. See, for example, Gibson and Bradshaw, *Angewandte Chemie*, International Edition in English, 7:919-930 (1968). The protected/activated salicylamide is substituted for the phthalimide in these methods.

The protected/activated salicylamide may also be alkylated by reacting the protected/activated salicylamide with an alkylating agent. The alkylating agent reacts with the nitrogen atom of the amide moiety of the salicylamide. The alkylating agent may be any known in the art, such as compounds of the formula

$$\text{X-R}^{10}\text{-R}^{11}$$

where

R^{10} is a linear or branched, $\text{C}_1\text{-C}_{20}$ alkylene, alkenylene, or alkynylene;

R^{10} is optionally substituted with $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkenyl, oxygen, nitrogen, sulfur, halogen, $-\text{OH}$, $\text{C}_1\text{-C}_4$ alkoxy, aryl, heteroaryl, or vinyl;

-11-

R^{10} is optionally interrupted with aryl, heteroaryl, vinyl, oxygen, nitrogen, or sulfur;

R^{11} is carboxyl or a salt thereof, carboxylate, nitrile, halogen, ester, amine or salt thereof, alcohol, or thiol; and

5 X is a suitable leaving group. Suitable leaving groups include, but are not limited to, halogens, such as chlorine, bromine, and iodine, and alcohols. Preferred alcohols include, but are not limited to, activated alcohols. Two preferred leaving groups are chlorine and bromine.


R^{10} may be substituted with an alkoxy moiety, such as methoxy or ethoxy.
10 Preferably, R^{10} is $-(CH_2)_n-$ where n is an integer from 1 to 12, more preferably from 7 to 9, and most preferably 7.

R^{11} is preferably a carboxyl or a salt thereof. Salts include, but are not limited to, organic and inorganic salts, for example, alkali-metal salts, such as sodium, potassium and lithium; alkaline-earth metal salts, such as magnesium, calcium or barium;
15 ammonium salts; basic amino acids, such as lysine and arginine; and organic amines, such as dimethylamine and pyridine. More preferably, R^{11} is a sodium salt of carboxyl.

 In a preferred embodiment, R^1 , R^2 , R^3 , and R^4 of the protected/activated salicylamide are hydrogen and R^{10} of the alkylating agent is $-(CH_2)_7-$ or $-(CH_2)_9-$. According to another preferred embodiment, R^1 , R^2 , and R^4 of the protected/activated
20 salicylamide are hydrogen, R^2 is chlorine, and R^{10} of the alkylating agent is $-(CH_2)_3-$ or $-(CH_2)_7-$. According to yet another preferred embodiment, R^1 , R^3 , and R^4 of the protected/activated salicylamide are hydrogen, R^3 is methoxy, and R^{10} of the alkylating agent is $-(CH_2)_7-$.

 Other suitable alkylating agents include, but are not limited to,
25 dicarboxylate alkylating agents, such as those having the formula

-12-



5

where

R^7 is a linear or branched, C_1 - C_{20} alkylene, alkenylene, or alkynylene;

R^7 is optionally substituted with C_1 - C_4 alkyl, C_1 - C_4 alkenyl, oxygen, nitrogen, sulfur, halogen, -OH, C_1 - C_4 alkoxy, aryl, heteraryl, or vinyl;

10 R^7 is optionally interrupted with aryl, heteroaryl, vinyl, oxygen, nitrogen, or sulfur;


R^8 and R^{11} are independently C_1 - C_4 alkyl or C_1 - C_4 haloalkyl; and

X is a suitable leaving group.

15 Suitable leaving groups include, but are not limited to, halogens and alcohols. Two preferred leaving groups are chlorine and bromine. Preferably, R^8 and R^{11} are independently C_1 - C_4 alkyl. Preferably, R^8 and R^{11} are the same. R^7 is preferably C_4 - C_{12} alkylene and more preferably C_7 - C_9 alkylene.

A preferred dicarboxylate alkylating agent has the formula

20



where

25

R^{12} and R^{13} are independently C_1 - C_4 alkyl;

X is a suitable leaving group; and

n is an integer from 2 to 12.

Preferably, n ranges from 3 to 10, more preferably from 4 to 8, and most preferably from 6 to 8. Non-limiting examples of dicarboxylate alkylating agents include

-13-

2-(6-bromohexyl)-malonic acid diethyl ester and 2-(8-bromooctyl)malonic acid diethyl ester, which are available from Allied Signal, Inc. of Morristown, NJ.

The reaction between the alkylating agent and the protected/activated salicylamide is preferably carried out in the presence of a slight molar excess of protected/activated salicylamide relative to alkylating agent. Generally, the molar ratio of protected/activated salicylamide to alkylating agent ranges from about 1:1 to about 1:0.5, preferably from about 1:0.8 to about 1:0.99, and most preferably about 1:0.95.

The alkylating reaction is preferably performed in the presence of a suitable base, such as pyridine, picoline, tetramethylguanidine, triethylamine, diisopropylethylamine, sodium or potassium bicarbonate, sodium or potassium carbonate, or any combination of any of the foregoing. According to a preferred embodiment, the base is sodium carbonate. Generally, the reaction is performed in the presence of a slight molar excess of base relative to the protected/activated salicylamide.

The reaction may be carried out in solvents including, but not limited to, dimethylacetamide (DMAC); dimethylformamide (DMF); ketones, such as acetone, methylethylketone, and methylisobutylketone; and any combination of any of the foregoing. Preferably, the solvent is non-aqueous.

The alkylating reaction is generally performed at a temperature of from about 20 to about 100° C. The reaction is preferably performed at a temperature of from about 40 to about 80° C, from about 50 to about 80° C, or from about 60 to about 80° C. Most preferably, the alkylating reaction is performed at about 70° C. The reaction is typically performed at atmospheric pressure to full vacuum and preferably from about 22 to about 24" Hg of vacuum.

The reaction mixture prior and during the alkylating reaction preferably contains less than 5%, more preferably less than 3%, and most preferably less than 1% by weight of water, based upon 100% total weight of reaction mixture.

The reaction is generally performed for a time sufficient to ensure the complete reaction of the protected/activated salicylamide. The reaction duration varies depending on the starting materials. Generally, the reaction is allowed to run for a time sufficient so that at least about 90% and preferably 99% of the limiting reagent, *i.e.*, the

-14-

alkylating agent, has been consumed, but is stopped before significant side reaction product build up. This reduces or eliminates the need for purification of the final product. Preferably, it is performed for from about 2 to about 18 hours, more preferably from about 3 to about 5 hours, and most preferably about 4 hours.

5 Carsalam and carsalam derivatives are preferably alkylated in the presence of a slight molar excess of base. A preferred base for such an alkylation reaction is sodium carbonate. A molar excess of sodium carbonate relative to carsalam or carsalam derivative is generally used. More preferably, the carsalam or the carsalam derivative is alkylated by sequentially adding sodium carbonate to a solvent, such as those described
10 above (e.g. DMAC); adding carsalam or the carsalam derivative to the solution; and adding a dicarboxylate alkylating agent to the solution. The alkylating agent is preferably added to the solution immediately following the addition of carsalam or carsalam derivative and more preferably within about 10 seconds after the completion of the carsalam or carsalam derivative addition. When the base, in this case sodium carbonate,
15 is reacted with the carsalam or carsalam derivative, carsalam-sodium or carsalam derivative-sodium and sodium bicarbonate are formed. While carsalam has a solubility of about 30% in DMAC, carsalam-sodium only has a solubility of about 6% in DMAC. Sodium bicarbonate can react with the carsalam or carsalam derivative resulting in the formation of carbonic acid, which may further react to form water. Generally, water
20 significantly reduces the efficacy of the alkylating agent. In order to minimize the reaction of sodium bicarbonate with the carsalam or carsalam derivative, the carsalam or carsalam derivative is preferably reacted with a molar excess of sodium carbonate. The water content of the reaction mixture may also be reduced by performing the reaction in a low pressure atmosphere (e.g. a vacuum).

25 According to another embodiment, the carsalam-sodium or carsalam derivative-sodium is isolated prior to being reacted with the alkylating agent in order to reduce water content.

 The alkylation reaction may be performed with alcohols under Mitsunobu conditions. See Mitsunobu, W. and Sano, J., *J. Amer. Chem. Soc.*, 94:674 (1972). Such
30 alkylation reactions are performed in the presence of triphenylphosphene (PPh₃) and

-15-

dialkyl azodicarboxylates, such as diisopropyl azodicarboxylate (DIAD). The products of this reaction may be hydrolyzed to the corresponding alkylated salicylamides.

The protected/activated alkylated salicylamide is then (a) deprotected and deactivated, (b) optionally, hydrolyzed, and (c) optionally, decarboxylated (when
5 alkylated with a dicarboxylate alkylating agent) to yield the alkylated salicylamide. Typically, these steps entail the removal of the protecting and activating groups from the salicylamide. The decarboxylate step entails removal of a carboxylate moiety from the alkylated salicylamide. The protecting and activating groups may be removed by acidic, basic and/or neutral hydrolysis as known in the art.

10 When alkylated with a dicarboxylate alkylating agent, the carboxylate moiety or moieties of the alkylated salicylamide may optionally be hydrolyzed to form a carboxylic acid moiety or carboxylic acid moieties or carboxylate salt. The protecting and activating groups and one of the carboxylate groups may be removed and the remaining carboxylate group may be hydrolyzed by acidic, basic and/or neutral hydrolysis
15 as known in the art.

Neutral hydrolysis may be performed, for example, with super-heated water at a temperature of from about 100 to about 250° C.

Deprotection

20 The salicylamide may be deprotected by any method known in the art, such as acidic, basic, or neutral hydrolysis. Deprotection is preferably performed by basic hydrolysis. Basic hydrolysis may be performed, for example, with aqueous sodium carbonate or aqueous sodium hydroxide. According to one embodiment, basic hydrolysis is performed with aqueous sodium hydroxide at a temperature of from about 78 to about
25 98° C.

Another method of deprotecting is by acidic hydrolysis. Acidic hydrolysis may be performed, for example, with aqueous hydrochloric acid or aqueous trifluoroacetic acid. For example, acidic hydrolysis may be performed with aqueous hydrochloric acid in acetone at a temperature of from about 25 to about 65° C.
30 According to one embodiment, acidic hydrolysis is performed at a pH of about 3.5 to 4.5

-16-

and preferably at about 4. The acidic hydrolysis process may also deactivate the salicylamide.

Deactivation

5 The activating group may be removed by any method known in the art. When acidic or basic hydrolysis is performed to deprotect the salicylamide, the activating group may be removed by neutralization. For example, when deprotection is performed by basic hydrolysis, the salicylamide may be deactivated by adding an aqueous acid, such as hydrochloric acid or aqueous trifluoroacetic acid. When deprotection is performed by
10 acidic hydrolysis, the salicylamide may be deactivated by adding an aqueous basic.

Hydrolysis

 Optionally, the alkylated salicylamide may be further reacted to modify the end group(s) of the alkylating moiety as well as the oxygen group attached to the
15 phenyl ring. For example, the end group -CN or -C(O)O-CH₂-CH₃ may be modified to -COOH or a salt thereof. This may be accomplished by methods known in the art, such as neutralization and acidic, basic, and neutral hydrolysis. Generally, hydrolysis of the salicylamide is performed by neutralizing the deprotected and deactivated salicylamide. When the salicylamide is deprotected by basic hydrolysis, the free acid of the
20 salicylamide is, for example, recovered by neutralization with an aqueous acid, such as hydrochloric acid.

Decarboxylation

 If a monocarboxylic salicylamide is desired and the salicylamide has been
25 alkylated with a dicarboxylate alkylating agent, the prepared alkylated salicylamide may be decarboxylated. The decarboxylation step is performed either before or after the deprotecting and deactivating steps and optional hydrolysis step. Preferably, decarboxylation is performed after the deprotecting and deactivating steps and optional hydrolysis step.

-17-

The decarboxylation step removes one of the carboxylate moieties from the alkylated salicylamide. Decarboxylation can be performed by any method known in the art, such as acidic hydrolysis as discussed above. In order to control foaming due to the release of carbon dioxide, the reaction may be performed in the presence of acetone.

5 Decarboxylation can also be performed by heating the alkylated salicylamide in a high boiling point organic solvent, such as xylenes, toluene, heptane, dimethyl acetamide (DMA or DMAC), dimethyl formamide (DMF), methyl sulfoxide, isoparaffins (*e.g.* isopar-G, isopar-H, isopar-L, and isopar-K available from Exxon Chemicals of Houston, TX), and any combination of any of the foregoing. The organic
10 solvent preferably has a boiling point of at least 110° C and more preferably of at least 140° C. The decarboxylation reaction is preferably performed at a temperature ranging from about 140 to about 20° C and more preferably ranging from about 140 to about 160° C. The temperature at which the reaction is performed should be sufficient to remove one of the carboxylate groups at the end of the added alkyl chain.

15 Preferably, any water in the reaction mixture is removed prior to heating. Water may be removed from a reaction mixture containing the free acid of the alkylated salicylamide (which is formed if the alkylated salicylamide is hydrolyzed as described in the "Hydrolysis" section above) as follows. The alkylated salicylamide is mixed with an organic solvent in which it is soluble, such as xylenes. The aqueous layer is then
20 extracted, which in this case is the lower layer, leaving the alkylated salicylamide in xylenes. The reaction mixture may then be heated to decarboxylate the alkylated salicylamide.

The reaction mixture prior and during the decarboxylation reaction preferably contains less than 5%, more preferably less than 3%, and most preferably less
25 than 1% by weight of water, based upon 100% total weight of reaction mixture.

The decarboxylation step may also be performed neat (*i.e.* without a solvent) by heating the deprotected, deactivated, and, optionally, hydrolyzed alkylated salicylamide to a temperature ranging from about 140 to about 200° C.

-18-

The deprotecting, deactivating, hydrolyzing, and decarboxylating steps may be performed at a temperature of from about 20 to about 200° C. According to one embodiment, the deprotecting and deactivating step is performed at a temperature of from about 20 to about 100° C and preferably from about 90 to about 100° C.

5 Suitable solvents for the protected/activated alkylated salicylamide in the deprotecting, deactivating, decarboxylating, and hydrolyzing step include, but are not limited to, water, organic solvents, such as ethanol, dimethylacetamide (DMAC), dimethylformamide (DMF), ketones (*e.g.* acetone, methylethylketone, and methylisobutylketone), and any combination of any of the foregoing.

10 When the protected/activated salicylamide is carsalam or a derivative thereof, the alkylated salicylamide may be deprotected by hydrolysis, such as basic hydrolysis. This causes the bonds between the carbonyl group and the adjacent oxygen atoms to cleave, thereby deprotecting the hydroxyl moiety. Hydrolysis may be carried out under conditions known in the art.

15 After hydrolysis of the carsalam or carsalam derivative, the activated salicylamide may be deactivated by methods known in the art. For example, hydrochloric acid may be added to the activated alkylated salicylamide until the pH of the reaction mixture is from about 3.5 to about 4.5 or until the pH is less than about 4. This causes the bond between the carbonyl moiety and the nitrogen atom of the amide moiety of the
20 salicylamide to cleave and release carbon dioxide. The hydrochloric acid may also remove one of the carboxylate moieties and hydrolyze the remaining carboxylate moiety (when a dicarboxylate alkylating agent is used).

 Alternatively, after hydrochloric acid is added to deactivate the alkylated salicylamide, the alkylated salicylamide can be decarboxylated by heating it in xylenes
25 or other high boiling point organic solvent, such as those discussed above, to reflux or near reflux. For example, when xylene is used as the solvent, the mixture is preferably heated to a temperature ranging from about 105 to about 140° C.


 Salts of the alkylated salicylamide may be formed by any method known in the art. For example, the acid form of the alkylated salicylamide, *i.e.*, where the
30 alkylated salicylamide has a -COOH moiety, may be converted into the corresponding

-19-

sodium salt by reacting it with sodium hydroxide. Suitable salts include, but are not limited to, organic and inorganic salts, for example alkali-metal salts, such as sodium, potassium and lithium; alkaline-earth metal salts, such as magnesium, calcium or barium; ammonium salts; basic amino acids, such as lysine or arginine; and organic amines, such as dimethylamine or pyridine. Sodium salts include, but are not limited to, mono-, di-, and other multi-valent sodium salts. A preferred salt is the disodium salt. The salts may also be solvates, including ethanol solvates, and hydrates. The term "solvate" as used herein includes, but is not limited to, a molecular or ionic complex of molecules or ions of a solvent, such as ethanol, with ions or molecules of the compounds of the present invention.

Optionally, the alkylated salicylamide may be further reacted to modify the end group of the alkylating moiety. For example, the end group $-\text{CN}$ or $-\text{C}(\text{O})\text{O}-\text{CH}_2-\text{CH}_3$ may be modified to $-\text{COOH}$ or a salt thereof. This may be accomplished by methods known in the art, such as acidic and basic hydrolysis.

The present method may be used to prepare alkylated salicylamides having the formula



where R^1 , R^2 , R^3 , R^4 , R^{10} , and R^{11} are defined as above. Special mention is made of *N*-(5-chlorosalicyloyl)-8-aminocaprylic acid, *N*-(10-[2-hydroxybenzoyl]amino)decanoic acid, *N*-(8-[2-hydroxybenzoyl]amino)caprylic acid, *N*-(4-methoxysalicyloyl)-8-aminocaprylic acid, and their salts, including, but not limited to, sodium salts (such as their monosodium and disodium salts).

The alkylated salicylamides of the present invention may be purified by recrystallization or fractionation on one or more chromatographic supports. Fractionation may be performed on suitable chromatographic supports, such as silica gel or alumina,

-20-


using solvent mixtures such as acetic acid/butanol/water as the mobile phase; reverse phase column supports using trifluoroacetic acid/acetonitrile mixtures as the mobile phase; and ion exchange chromatography using water as the mobile phase. The alkylated salicylamides may also be purified to remove impurities, such as inorganic salts, by extraction with a lower alcohol, such as methanol, butanol, or isopropanol.

The method of the present invention uses readily available and inexpensive starting materials and provides a cost-effective method for preparing and isolating salicylamide intermediates and alkylated salicylamides. The method is simple to perform and is amenable to industrial scale-up for commercial production.

The following examples are intended to describe the present invention without limitation. All percentages are by weight unless otherwise specified.

Example 1

Preparation of 5-chlorosalicylamide



All chemicals are available from Sigma-Aldrich (Highland, IL). 5-chlorosalicylic acid (2000g, 1 equiv., 11.59 moles) and reagent grade n-butanol (5000mL, 4.7 equiv, 54.64 moles) were charged to a 12L four neck, round bottom flask equipped with a thermocouple temperature readout, overhead stirrer, and 1L Dean-Stark trap/reflux condenser. The Dean-Stark trap was pre-charged with an additional 1000mL of n-butanol. The reaction set up was purged with dry nitrogen and a dry nitrogen atmosphere was maintained during the reaction.

-21-

Concentrated sulfuric acid (50g, 0.04 equiv., 0.51 moles) was added and a heating mantle was placed on the reaction flask. The reaction was heated to reflux and maintained at reflux for about 30 hours (until >95% conversion to the ester was found by HPLC).

5 The heating mantle was removed and the reaction mixture allowed to cool to ambient temperature. The Dean-Stark trap was drained and removed.

1000mL deionized water was charged to the reaction mixture, while keeping the temperature at about 28° C, and stirred for 10 minutes. The aqueous layer was allowed to settle (about 30 minutes) and was then siphoned off and discarded.

10 1000mL 10 wt% sodium bicarbonate was charged and the mixture was stirred for 10 minutes. The aqueous layer was allowed to settle (about 30 minutes to one hour) and was then siphoned off and discarded.

500mL deionized water was charged and the mixture stirred for 10 minutes. The aqueous layer was allowed to settle (about 30 minutes) and was then siphoned off and discarded. This wash was repeated with another 500mL of deionized water. The aqueous phase was removed and discarded.

15 The reactor was set for atmospheric distillation into a tared 5L receiver. Distillation was run until the pot temperature rose to between about 140 and 150°C.

20 The reactor was then set for vacuum distillation. The pressure was slowly lowered to 500mm Hg. The pot temperature fell and the remaining n-butanol and n-butyl ether (a reaction byproduct) distilled off.

The heating was stopped and the reaction mixture allowed to cool to ambient temperature. The vacuum was broken. The distillate was poured into a large separatory funnel and the upper organic phase was saved for later recovery or reuse in other batches of this process.

25 The pot residue was cooled to about 23° C and 8000mL anhydrous methanol was charged.

The pot residue was vacuum filtered (Buchner funnel and WHATMAN® #1 paper (Whatman Paper Ltd., Kent, England) were wetted with n-butanol) into a 22L,

-22-

five neck flask set up with an overhead stirrer, reflux condenser, thermocouple temperature readout, gas inlet adapter, and nitrogen atmosphere.

The flask was setup with an ammonia cylinder with regulator, and an oil bubbler. The headspace of the reactor was flushed with anhydrous ammonia (about 600g, 4 equiv., 35 moles), adding the ammonia so that the bubbler just barely bubbled. The reaction was continued approximately 18-24 hours at ambient temperature and pressure until >99% conversion by HPLC.

The reactor was set for atmospheric distillation into a tared 5L flask. About 4000mL of the solvent was distilled off. The pot mixture formed a precipitate about half way through this distillation. The distillate was saved for reuse in other batches of this process.

The pot residue was cooled to between about 40° C and 50° C. Deionized water (4000mL) was slowly charged to the pot slurry. The pot slurry became thicker during this water charge.

The slurry was cooled to about 5° C with an ice bath. The pH of the slurry was adjusted to about 4 with concentrated hydrochloric acid.

The solid product was recovered by vacuum filtration. The filter cake was washed with 2000mL deionized water. The product was dried in a 50° C vacuum oven with full vacuum for about 20 hours. About 1880g of material was obtained. The yield was about 95%.

Example 2

Preparation of N-(5-chlorosalicyloyl)-8-aminocaprylic acid

To a clean, dry, 200 gallon glass-lined reactor, 178 L of dry acetonitrile is added. The agitator is set to 100-125 rpm and the reactor contents are cooled to about 9° C. 74 kg of 5-chloro salicylamide, available from Polycarbon Industries of Leominster, MA, is charged to the reactor and the charging port is closed. 47 L of dry pyridine is charged to the reactor. The resulting slurry is cooled to about 9° C. Cooling is applied to the reactor condenser and valve overheads are set for total reflux. Over 2 hours, 49.7 kg of ethylchloroformate is charged to the 200 gallon reactor while maintaining the batch temperature at about 14° C. Note that ethylchloroformate can

-23-

contain 0.1% phosgene and is extremely reactive with water. The reaction is highly exothermic and requires the use of a process chiller to moderate reaction temperature.

The reactor contents are agitated for 30 minutes at 10-14° C, once the ethylchloroformate addition is complete. The reactor contents are then heated to about 85° C over 25 minutes, collecting all distillate into a receiver. The reactor contents are held at 85-94° C for approximately 6 hours, collecting all distilled material into a receiver. The reaction mixture is sampled and the conversion (>90%) monitored by HPLC. The conversion is found to be 99.9% after 6 hours. The reactor contents are cooled to about 19° C over a one-hour period. 134 L of deionized water is charged to the reactor. A precipitate formed immediately. The reactor contents are cooled to about 5° C and agitated for 10.5 hours. The product continued to crystallize out of solution. The reactor slurry is centrifuged. 55 L of deionized water is charged to the 200-gallon, glass-lined reactor and the centrifuge wet cake is washed. The intermediate is dried under full vacuum (28" Hg) at 58° C for 19.5 hours. The yield is 82.6 kg 6-chloro-2H-1,3-benzoxazine-2,4(3H)-dione. This intermediate is packaged and stored so that it is not exposed to water.

In the next preparation, absolutely no water can be tolerated in the steps up to the point where distilled water is added.

222 L of dry dimethylacetamide is charged to a dry 200 gallon glass-lined reactor. The reactor agitator is set to 100-125 rpm. Cooling is applied to the condenser and valve reactor overheads are set for distillation. 41.6 kg of dry anhydrous sodium carbonate is charged to the reactor and the reactor charging port is closed. Caution is used due to some off-gassing and a slight exothermic reaction. 77.5 kg of dry 6-chloro-2H-1,3-benzoxazine-2,4(3H)-dione is charged to the reactor. Quickly, 88 kg of dry ethyl-8-bromooctanoate is charged to the reactor. The reaction is evacuated to 22-24 inches of vacuum and the reactor temperature is raised to 65-75° C. The reactor temperature is maintained and the contents are watched for foaming. The reactor mixture is sampled and monitored for conversion by monitoring for the disappearance of the bromo ester in the reaction mixture by gas chromatography. The reaction is complete after 7 hours. The vacuum is broken and the reactor contents are cooled to 45-50° C. The contents are

-24-

centrifuged and the filtrate sent into a second 200 gallon glass-lined reactor. 119 L of ethanol (200 proof denatured with 0.5% toluene) is charged to the first 200 gallon reactor, warmed to about 45° C and the filter cake washed with warm ethanol and this wash is charged to the reaction mixture in the second 200 gallon reactor.

5 The agitator is started on the second 200 gallon reactor. The reactor contents are cooled to about 29° C. 120 L distilled water is slowly charged to the second reactor, with the water falling directly into the batch. The reactor contents are cooled to about 8° C. The intermediate comes out of solution and is held for 9.5 hours. The resultant slurry is centrifuged. 70 L ethanol is charged to the reactor, cooled to about 8°
10 C, and the centrifuge cake is washed. The wet cake is unloaded into double polyethylene bags placed inside a paper lined drum. This yields ethyl 8-(6-chloro-2H-1,3-benzoxazine-2,4(3H)-dionyl)octanoate.

 400 L purified water, USP and 45.4 kg sodium hydroxide pellets are charged to a 200 gallon glass-lined reactor and the agitator is set to 100-125 rpm. 123.5
15 kg of the ethyl 8-(6-chloro-2H-1,3-benzoxazine-2,4(3H)-dionyl)octanoate wet cake is charged to the reactor. The charging port is closed. Cooling water applied to the condenser and the valve reactor overheads are set for atmospheric distillation. The reactor contents are heated to about 98° C and the conversion is monitored by HPLC. Initially (approximately 40 minutes) the reactor refluxes at about 68° C, however, as the
20 ethanol is removed (over 3 hours) by distillation the reactor temperature rises to about 98° C. The starting material disappears, as determined by HPLC, at approximately 4 hours. The reactor contents are cooled to about 27° C. 150 L purified water, USP is charged to an adjacent 200 gallon glass-lined reactor and the agitator is set to 100-125 rpm. 104 L concentrated (12M) hydrochloric acid is charged to the reactor and cooled
25 to about 24° C. The saponified reaction mixture is slowly charged (over 5 hours) to the 200 gallon glass-lined reactor. The material (45 L and 45 L) is split into 2 reactors (200 gallons each) because of carbon dioxide evolution. The product precipitated out of solution. The reaction mixture is adjusted to pH 2.0-4.0 with a 50% sodium hydroxide solution (2L water, 2 kg sodium hydroxide). The reactor contents are cooled to about 9-
30 15° C. The intermediate crystallizes out of solution over approximately 9 hours. The

-25-

reactor slurry is centrifuged to isolate the intermediate. 50 L purified water, USP is charged to a 200 gallon glass-lined reactor and this rinse is used to wash the centrifuge wet cake. The wet cake is unloaded into double polyethylene bags placed inside a plastic drum. The *N*-(5-chlorosalicyloyl)-8-aminocaprylic acid is dried under vacuum (27" Hg) at 68° C for 38 hours. The dry cake is unloaded into double polyethylene bags placed inside a 55-gallon, steel unlined, open-head drums with a desiccant bag placed on top. This yields *N*-(5-chlorosalicyloyl)-8-aminocaprylic acid.

10 All patents, publications, applications, and test methods mentioned above are hereby incorporated by reference. Many variations of the present matter will suggest themselves to those skilled in the art in light of the above detailed description. All such obvious variations are within the patented scope of the appended claims.

-26-

What is claimed is:

- 1 1. A method for preparing a salicylamide comprising the step of
2 reacting a C₄ or higher alkyl ester of salicylic acid or a derivative thereof with at least one
3 amine selected from the group consisting of monoalkylamines, dialkylamines, ammonia,
4 and any combination of any of the foregoing in alcohol to yield the salicylamide.
- 1 2. The method of claim 1, wherein the C₄ or higher alkyl ester of
2 salicylic acid or a derivative thereof is a C₄-C₈ alkyl ester of salicylic acid or a derivative
3 thereof.
- 1 3. The method of claim 2, wherein the C₄ or higher alkyl ester of
2 salicylic acid or a derivative thereof is a butyl ester of salicylic acid or a derivative
3 thereof.
- 1 4. The method of claim 1, wherein the alcohol is selected from the
2 group consisting of C₁-C₄ alcohols, glycols, and any combination of any of the foregoing.
- 1 5. The method of claim 4, wherein the alcohol is methanol.
- 1 6. The method of claim 1, wherein the amine is selected from the
2 group consisting of monomethylamine, monoethylamine, dimethylamine, diethylamine,
3 ammonia, and any combination of any of the foregoing.
- 1 7. The method of claim 1, wherein the amine is ammonia.
2
- 3 8. The method of claim 7, wherein the ammonia is anhydrous
4 ammonia.

-27-

1 9. The method of claim 1, wherein the monoalkylamine is 8-
2 aminocaprylic acid.


1 10. The method of claim 1, wherein the C₄ or higher alkyl ester is
2 reacted in an environment substantially free of water.

1 11. The method of claim 10, wherein the environment has less than
2 about 1% by weight of water.

1 12. The method of claim 1, wherein the reaction is performed at a
2 temperature of from about 25 to about 80° C.

1 13. The method of claim 1, wherein the reaction is performed at a
2 pressure of from about 1 to about 10 atm.

1 14. The method of claim 1, wherein the salicylamide has the formula
2



9 wherein

10 R¹, R², R³, and R⁴ are independently hydrogen, -OH, -O-R⁵, substituted or
11 unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted
12 alkoxy, substituted or unsubstituted aryl, carboxy, substituted or unsubstituted
13 alkoxycarbonyl, halogen, nitrile, -OC(O)CH₃, -SO₃H, or -NR⁶R⁷;

14 R⁵ is hydrogen, alkyl, or aryl; and

15 R⁶ and R⁷ are independently hydrogen, C₁-C₄ alkyl, or oxygen.

-28-

1 15. The method of claim 14, wherein the salicylamide is 5-
2 chlorosalicylamide.

1 16. The method of claim 14, wherein the salicylamide is 4-methoxy
2 salicylamide.

1 17. The method of claim 1, further comprising the step of reacting
2 salicylic acid or a derivative thereof with a C₄ or higher alcohol in the presence of at least
3 one of sulfuric acid, a sulfonic acid, and a mineral acid to form the C₄ or higher alkyl
4 ester of salicylic acid or a derivative thereof.

1 18. The method of claim 17, wherein the C₄ or higher alcohol is a
2 primary alcohol.

1 19. The method of claim 18, wherein the C₄ or higher alcohol is a C₄-
2 C₈ alcohol.

1 20. The method of claim 18, wherein the C₄ or higher alcohol is n-
2 butanol.

1 21. The method of claim 17, wherein the sulfonic acid is p-toluene
2 sulfonic acid.

3
4 22. The method of claim 17, wherein the mineral acid is selected from
5 the group consisting of hydrochloric acid, hydrogen bromide, phosphoric acid, and any
6 combination of any of the foregoing.


1 23. The method of claim 17, wherein the reaction for forming the C₄
2 or higher alkyl ester is performed in the presence of sulfuric acid.

-29-

1 24. The method of claim 17, wherein water is removed during or after
2 formation of the C₄ or higher alkyl ester.

1 25. The method of claim 24, wherein water is removed during
2 formation of the C₄ or higher alkyl ester.

1 26. The method of claim 17, wherein the salicylic acid or derivative
2 thereof has the formula



9 wherein

10 R¹, R², R³, and R⁴ are independently hydrogen, -OH, -O-R⁵, substituted or
11 unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted
12 alkoxy, substituted or unsubstituted aryl, carboxy, substituted or unsubstituted
13 alkoxycarbonyl, halogen, nitrile, -OC(O)CH₃, -SO₃H, or -NR⁶R⁷;

14 R⁵ is hydrogen, alkyl, or aryl; and


15 R⁶ and R⁷ are independently hydrogen, C₁-C₄ alkyl, or oxygen.

1 27. A method for preparing a C₄ or higher alkyl ester of salicylic acid
2 or a derivative thereof, the method comprising the step of reacting salicylic acid or a
3 derivative thereof with a C₄ or higher alcohol in the presence of at least one of sulfuric
4 acid, a sulfonic acid, and a mineral acid to form the C₄ or higher alkyl ester of salicylic
5 acid or a derivative thereof.

1 28. The method of claim 27, wherein the alcohol is a primary alcohol.

-30-

- 1 29. The method of claim 27, wherein the alcohol is a C₄-C₈ alcohol.
- 1 30. The method of claim 29, wherein the alcohol is n-butanol.
- 1 31. The method of claim 27, wherein the sulfonic acid is p-toluene
2 sulfonic acid.
- 1 32. The method of claim 27, wherein the mineral acid is selected from
2 the group consisting of hydrochloric acid, hydrogen bromide, phosphoric acid, and any
3 combination of any of the foregoing.
- 1 33. The method of claim 27, wherein the reaction is performed in the
2 presence of sulfuric acid.
- 1 34. The method of claim 27, wherein water is removed during or after
2 formation of the C₄ or higher alkyl ester.
- 1 35. The method of claim 27, wherein water is removed during
2 formation of the C₄ or higher alkyl ester.
- 1 36. The method of claim 27, wherein the salicylic acid or derivative
2 thereof has the formula



wherein

R^1 , R^2 , R^3 , and R^4 are independently hydrogen, -OH, -O- R^5 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, carboxy, substituted or unsubstituted alkoxycarbonyl, halogen, nitrile, -OC(O)CH₃, -SO₃H, or -NR⁶R⁷;

R^5 is hydrogen, alkyl, or aryl; and

R^6 and R^7 are independently hydrogen, C₁-C₄ alkyl, or oxygen.

37. A method for preparing an alkylated salicylamide comprising the steps of:

(a) reacting a C₄ or higher alkyl ester of salicylic acid or a derivative thereof with at least one amine selected from the group consisting of monoalkylamines, dialkylamines, ammonia, and any combination of any of the foregoing in alcohol to yield a first salicylamide; and

(b) alkylating the first salicylamide to form the alkylated salicylamide.

38. The method of claim 37, wherein step (b) comprises:

(i) protecting and activating the first salicylamide to form a protected/activated salicylamide;

(ii) alkylating the protected/activated salicylamide with an alkylating agent to form a protected/activated alkylated salicylamide; and

(iii) deprotecting and deactivating the protected/activated alkylated salicylamide to form the alkylated salicylamide.

-32-

1 39. The method of claim 37, wherein the alkylated salicylamide is *N*-
2 (5-chlorosalicyloyl)-8-aminocaprylic acid or a salt thereof.

1 40. The method of claim 37, wherein the alkylated salicylamide is *N*-
2 (10-[2-hydroxybenzoyl]amino)decanoic acid or a salt thereof.

1 41. The method of claim 37, wherein the alkylated salicylamide is *N*-
2 (8-[2-hydroxybenzoyl]amino)caprylic acid or a salt thereof.

1 42. A method for preparing an alkylated salicylamide comprising the
2 steps of:

- 3 (a) reacting salicylic acid or a derivative thereof with a C₄ or higher
4 alcohol in the presence of at least one of sulfuric acid, a sulfonic acid, and a mineral acid
5 to form a C₄ or higher alkyl ester of salicylic acid or a derivative thereof.
6 (b) converting the C₄ or higher alkyl ester into a first salicylamide;
7 (c) alkylating the first salicylamide to form the alkylated salicylamide.

1 43. The method of claim 42, wherein step (b) comprises reacting the
2 C₄ or higher alkyl ester with at least one amine selected from the group consisting of
3 monoalkylamines, dialkylamines, ammonia, and any combination of any of the foregoing
4 in alcohol to yield the first salicylamide.

1 44. The method of claim 42, wherein step (c) comprises:

- 2 (i) protecting and activating the first salicylamide to form a
3 protected/activated salicylamide;
4 (ii) alkylating the protected/activated salicylamide with an alkylating
5 agent to form a protected/activated alkylated salicylamide; and
6 (iii) deprotecting and deactivating the protected/activated alkylated
7 salicylamide to form the alkylated salicylamide.

-33-

1 45. The method of claim 43, wherein the alkylated salicylamide is *N*-
2 (5-chlorosalicyloyl)-8-aminocaprylic acid or a salt thereof.

1 46. The method of claim 43, wherein the alkylated salicylamide is *N*-
2 (10-[2-hydroxybenzoyl]amino)decanoic acid or a salt thereof.

1 47. The method of claim 43, wherein the alkylated salicylamide is *N*-
2 (8-[2-hydroxybenzoyl]amino)caprylic acid or a salt thereof.

1 48. The method of claim 43, wherein the alkylated salicylamide is *N*-
2 (4-methoxysalicyloyl)-8-aminocaprylic acid or a salt thereof.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/18118

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07C 231/00, 233/05

US CL : 564/134, 170

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 564/134, 170

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
EAST, WESTElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CASONLINE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,795,832 A (LEINEN et al) 03 January 1989, col 2, lines 8-64.	1-26
Y	US 5,442,092 A (CHOPDEKAR et al) 15 August 1995, col 3, lines 5-68 and col 4, lines 1-12.	1-36.
Y	HOSSAIN M.N. O,O-Diethyldithiophosphoric acid- A new condensing agent for acylation of amines by carboxylic acid. Indian Journal of Chemistry, November 1990, Vol 29B, pages 1062-1063, see the entire document.	1-36

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

07 AUGUST 2001

Date of mailing of the international search report

04 SEP 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SHAIENDRA KUMAR

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/18118

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BROWNSORT. P.A. Nitrile Sulfides. Part 7. Synthesis of (1)Benzopyrano(4,3-c)isothiazoles and Isothiazolo(4,3-c)quinolines. J. Chem. Soc. Perkin Trans. I 1987, Vol 11, pages 2339-44, especially page 2342.	37-48